Back to Search
DR. EVELYN ABENA OPPONGWAA ABOAGYE MD
MD
Pediatrics Physician
NPI: 1194992172Individual
Specialties, Licenses & Credentials
Pediatrics PhysicianPrimary
Pediatrics
Code: 208000000X
2010028332(MO)57013380(OH)0101275037(VA)
Research & Publications (20)
The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity.
PMID 19638587·Cancer Res·2009
7-preclinical
Monitoring predominantly cytostatic treatment response with 18F-FDG PET.
PMID 19403880·J Nucl Med·2009
6-review
A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients.
PMID 19117994·Cancer Res·2009
8-other
Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901.
PMID 18790789·Mol Cancer Ther·2008
7-preclinical
The biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 18F-AH111585 in healthy volunteers.
PMID 18794263·J Nucl Med·2008
8-other
Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945.
PMID 18483267·Cancer Res·2008
7-preclinical
Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients.
PMID 18483090·J Nucl Med·2008
3-trial
Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes.
PMID 17639391·Cancer Chemother Pharmacol·2008
3-trial
Design, synthesis, and biological characterization of a caspase 3/7 selective isatin labeled with 2-[18F]fluoroethylazide.
PMID 19049429·J Med Chem·2008
7-preclinical
Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.
PMID 17333178·Eur J Nucl Med Mol Imaging·2007
8-other
Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity.
PMID 18089709·Mol Cancer Ther·2007
7-preclinical
Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography.
PMID 16951168·Cancer Res·2006
7-preclinical
In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.
PMID 16885362·Cancer Res·2006
7-preclinical
Quantifying the activity of adenoviral E1A CR2 deletion mutants using renilla luciferase bioluminescence and 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography imaging.
PMID 16982761·Cancer Res·2006
7-preclinical
Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors.
PMID 16568206·Eur J Nucl Med Mol Imaging·2006
8-other
Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies.
PMID 16670384·J Natl Cancer Inst·2006
6-review
Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients.
PMID 16707610·Clin Cancer Res·2006
3-trial
Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-alpha and the transcriptional repressor PLZF.
PMID 15647773·Gene Ther·2005
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 375 FOUR LEAF LN
CHARLOTTESVILLE, VA 22903 - Phone
- (434) 243-0700
Quick Facts
- NPI
- 1194992172
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 3
- Locations
- 2
- Publications
- 20
Are you this provider?
Claim Your Profile